Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
You may also be interested in...
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
GlaxoSmithKline filed an Rx-to-OTC switch application for Xenical (orlistat 60 mg) in June, the firm announced July 28